Third Harmonic Bio, Inc. financial data

Symbol
THRD on Nasdaq
Industry
Pharmaceutical Preparations
Location
1700 Montgomery Street, Suite 210, San Francisco, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4.96K % -9.63%
Debt-to-equity 3.21 % +13.4%
Return On Equity -12.3 % +2.61%
Return On Assets -12 % +3.01%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 41.1M shares +1.78%
Common Stock, Shares, Outstanding 40.7M shares +2.71%
Entity Public Float 86.1M USD
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 40.6M shares +2.49%
Weighted Average Number of Shares Outstanding, Diluted 40.6M shares +2.49%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 26.5M USD +1.59%
General and Administrative Expense 20.1M USD +7.23%
Operating Income (Loss) -46.6M USD -3.95%
Nonoperating Income (Expense) 13.9M USD +152%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -32.7M USD +9.9%
Earnings Per Share, Basic 0.82 USD/shares +36.8%
Earnings Per Share, Diluted 0.82 USD/shares +36.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 255M USD -8.2%
Assets, Current 261M USD -6.83%
Deferred Income Tax Assets, Net 25.5M USD +39.8%
Property, Plant and Equipment, Net 145K USD -24.9%
Operating Lease, Right-of-Use Asset 3.41M USD -16.8%
Other Assets, Noncurrent 620K USD -14.6%
Assets 266M USD -6.99%
Accounts Payable, Current 1.44M USD +7.15%
Liabilities, Current 6.35M USD +50.4%
Operating Lease, Liability, Noncurrent 2.79M USD -22.3%
Liabilities 9.14M USD +17%
Retained Earnings (Accumulated Deficit) -133M USD -32.7%
Stockholders' Equity Attributable to Parent 257M USD -7.66%
Liabilities and Equity 266M USD -6.99%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.29M USD +5.72%
Net Cash Provided by (Used in) Financing Activities 49K USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 40.7M shares +2.71%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.24M USD +6.46%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 270M USD -6.84%
Deferred Tax Assets, Valuation Allowance 25.5M USD +39.8%
Deferred Tax Assets, Gross 26.7M USD +34.9%
Operating Lease, Liability 3.59M USD -16.2%
Depreciation 12K USD +300%
Payments to Acquire Property, Plant, and Equipment 0 USD
Lessee, Operating Lease, Liability, to be Paid 4.33M USD -20.3%
Property, Plant and Equipment, Gross 204K USD 0%
Operating Lease, Liability, Current 801K USD +15.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.18M USD +2.71%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.15M USD +2.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 733K USD -35.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.21M USD +2.64%
Deferred Tax Assets, Operating Loss Carryforwards 12M USD +16%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.21M USD +2.64%
Operating Lease, Payments 1.13M USD +275%
Additional Paid in Capital 389M USD +3.03%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 8.88M USD +2.45%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%